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GWAS have yielded many candidate loci for complex diseases like obesity, but interpreting the biological
context of these findings has been difficult. Claussnitzer et al. (2015) use a sophisticated combination of
bioinformatic and experimental approaches to address this bottleneck for variants in the FTO locus that
associate with obesity.Genome-wide association studies (GWAS)
have revolutionized the search for the
genetic underpinnings of human disease.
Despite the identification of thousands of
single-nucleotide polymorphisms (SNPs)
associated with complex diseases,
GWAS has been the subject of two major
criticisms. First, for most conditions,
GWAS has failed to account for the lion’s
share of estimated heritable risk. Second,
even the best-documented ‘‘hits’’ have
defied biological explanation, and thus
true insight into disease mechanisms has
lagged. GWAS hits have been hard to
interpret because of uncertainty over
which exact SNP is causal, given the large
number of variants in linkage disequilib-
rium. This is compounded by the fact
that the vast majority of potentially causal
SNPs are located in non-coding regulatory
regions of the genome (Abecasis et al.,
2012). The practice of ‘‘mapping’’ such
SNPs to the nearest gene is misleading,
as SNPs may regulate gene expression
over large genomic distances (Ragvin
et al., 2010). Finally, GWAS hits give few
clues about which cell types may be
most relevant for a SNP, further limiting
confidence about the identity and function
of the causative SNP. Altogether, it is no
surprise that we understand little about
how specific SNPs contribute to the path-
ophysiology of complex disease. Into this
morass wade the authors of a study in
the New England Journal of Medicine,
utilizing a battery of computational and
experimental strategies to point the way
for others trying to make sense of GWAS
data (Claussnitzer et al., 2015).
The paper focuses on the FTO locus,
which contains intronic SNPs that strongly
associate with obesity in diverse popu-538 Cell Metabolism 22, October 6, 2015 ª20lations (reviewed in Tung et al., 2014).
FTO is expressed in hypothalamic neu-
rons that control appetite and energy
expenditure, and transgenic and knockout
studies have demonstrated an effect of
FTO copy number on adiposity (Church
et al., 2010; Fischer et al., 2009; Gao
et al., 2010), suggesting that FTO itself
could be the relevant target gene. How-
ever, in 2010, Ragvin and colleagues
recognized highly conserved synteny in
the FTO locus and demonstrated in zebra-
fish that this locus regulated expression
of the distal Irx3 homeobox gene in multi-
ple tissues during development (Ragvin
et al., 2010). Smemo et al., and now
Claussnitzer et al., used state-of-the-art
chromatin-capture sequencing technolo-
gies to confirm direct interactions be-
tween regions in the FTO locus and the
distant Irx3 and Irx5 genes in mouse and
zebrafish embryos and human fibroblastic
cell lines (Claussnitzer et al., 2015; Smemo
et al., 2014). Both groups provide compel-
ling eQTL data that SNPs in this region
associate with IRX3 and/or IRX5 expres-
sion, but not with FTO expression, in hu-
man cells (see Figure 1, top).
Claussnitzer et al. also identify the
causal SNP within the FTO locus using a
sophisticated bioinformatics approach.
A T-to-C transition (rs1421085) in perfect
linkage disequilibrium with the lead
SNP (rs1558902) identified by GWAS
is predicted to disrupt a conserved
motif that binds members of the ARID
family of transcription factors. Consistent
with this, overexpression or knockdown
of ARID5b in pre-adipocytes suppressed
or increased IRX3/5 expression, respec-
tively, in cells containing the intact motif,
but not the mutated motif. Using gene15 Elsevier Inc.editing, conversion of T to C at
rs1421085 increased IRX3/5 expression
to levels observed in carriers of the risk
allele, providing strong evidence that
this is in fact the causal SNP. And
because this site is conserved in mice,
gene editing approaches can be used to
produce mouse lines replicating the hu-
man T-to-C mutation, allowing explora-
tion of the mechanisms by which the
FTO locus causes obesity in vivo.
Which tissue mediates the actions of
this SNP? Most genetic variants that
affect body weight point to hypothalamic
regions that regulate food intake and
energy expenditure (Speliotes et al.,
2010). Consistent with this, Smemo
et al. showed that expression of a domi-
nant-negative IRX3 selectively in hypo-
thalamus in mice affects body weight
(Smemo et al., 2014). However, Clauss-
nitzer et al. observed that the SNPs in
the FTO intron are contained within a
‘‘super-enhancer’’ most active in cells of
mesenchymal origin, including adipose
tissue-derived mesenchymal cells. This
suggests a role for IRX3/5 in adipocyte
development and function. They noted
increased IRX3 expression in human
adipose stromal vascular fractions that
bear the risk allele and proposed that
one mechanism by which this SNP
promotes obesity is by favoring differen-
tiation of progenitor cells toward fat-
storing white adipocytes rather than fat-
burning beige adipocytes. Consistent
with this, expression of IRX3 in pre-adi-
pocytes promoted expression of a gene
program implicated in white adipose
tissue development and lipid storage,
whereas suppression of IRX3 favored
a developmental program reminiscent of
Figure 1. Variants in the FTO Locus Regulate IRX3/5 Expression to
Exert Effects on Body Weight
Top: Variants in the FTO locus regulate the expression of IRX3 and IRX5 via
binding the transcription factor ARID5B. Bottom: The consequences of altered
IRX3/5 expression may be manifested in the adipose lineage, with altered
beige fat development, and/or in the hypothalamus, via changes in food intake
and energy expenditure. See text for details.
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ally, transgenic expression
of a dominant-negative IRX3
in mature adipocytes mark-
edly suppressed weight
gain, and this was associated
with increased energy
expenditure.
The potential of beige
adipose tissue to increase en-
ergy expenditure and pro-
mote weight loss is currently
a topic of great interest. How-
ever, most (but not all) clinical
data indicate that the FTO risk
alleles are associated with
increased food intake and
not with reduced energy
expenditure (reviewed in
Tung et al., 2014), inconsis-
tent with a mechanism that
relies on beige fat activity.
Measuring subtle changes in
energy expenditure that
might account for relatively
small changes in weight
accrued over many years is
notoriously difficult. Short of
this, it will be important to
address whether the FTO lo-
cus affects the abundance of
beige fat in adult human pop-
ulations and whether such
differences are capable of
mediating physiologically sig-
nificant changes in human
weight (Sidossis and Kaji-
mura, 2015). Additionally,
both Smemo et al. andClaussnitzer et al. express dominant-
negative IRX3 under the control of ele-
ments expressed in mature neurons and
adipocytes, respectively, which may not
be the most relevant system for testing
the effects of what are believed to be
developmental genes. Altogether, the
cell type and mechanism by which the
FTO variant affects body weight is still un-
settled, and we should be mindful that
important activities in brain and adiposetissue are not mutually exclusive (see
Figure 1, bottom).
While questions remain, Claussnitzer
and colleagues have driven the field for-
ward by identifying the causal SNP and
by illuminating one mechanism by which
this variant could affect body weight.
More importantly, they have generated a
roadmap by which the community can
begin to elucidate the biology associated
with the GWAS data generated over theCell Metabolism 22, October 6past decade. These insights
will be essential to move us
toward the world of precision
medicine that we aspire to.ACKNOWLEDGMENTS
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